These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 15306598)

  • 21. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b.
    Hofgärtner WT; Polyak SJ; Sullivan DG; Carithers RL; Gretch DR
    J Med Virol; 1997 Oct; 53(2):118-26. PubMed ID: 9334922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy.
    Kurosaki M; Enomoto N; Murakami T; Sakuma I; Asahina Y; Yamamoto C; Ikeda T; Tozuka S; Izumi N; Marumo F; Sato C
    Hepatology; 1997 Mar; 25(3):750-3. PubMed ID: 9049230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations in the interferon-sensitivity determining region of hepatitis C virus and transcriptional activity of the nonstructural region 5A protein.
    Fukuma T; Enomoto N; Marumo F; Sato C
    Hepatology; 1998 Oct; 28(4):1147-53. PubMed ID: 9755255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations in two PKR-binding domains in chronic hepatitis C of genotype 3a and correlation with viral loads and interferon responsiveness.
    Yokozaki S; Katano Y; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
    J Med Virol; 2011 Oct; 83(10):1727-32. PubMed ID: 21837788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population?
    Macquillan GC; Niu X; Speers D; English S; Garas G; Harnett GB; Reed WD; Allan JE; Jeffrey GP
    J Gastroenterol Hepatol; 2004 May; 19(5):551-7. PubMed ID: 15086599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin.
    Yen YH; Hung CH; Hu TH; Chen CH; Wu CM; Wang JH; Lu SN; Lee CM
    Aliment Pharmacol Ther; 2008 Jan; 27(1):72-9. PubMed ID: 17973647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy.
    Liang CM; Hu TH; Lu SN; Hung CH; Huang CM; Wang JH; Yen YH; Chen CH; Chang KC; Tsai MC; Kuo YH; Lee CM
    J Viral Hepat; 2013 Nov; 20(11):761-9. PubMed ID: 24168255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Substitutions in interferon sensitivity-determining region and hepatocarcinogenesis after hepatitis C virus eradication.
    Yasuda S; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hayashi K; Toyoda H; Kumada T; Hirooka Y; Goto H
    J Gastroenterol Hepatol; 2018 Nov; 33(11):1904-1911. PubMed ID: 29744922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NS5A mutations predict biochemical but not virological response to interferon-alpha treatment of sporadic hepatitis C virus infection in European patients.
    Stratidaki I; Skoulika E; Kelefiotis D; Matrella E; Alexandrakis G; Economou A; Kouroumalis E
    J Viral Hepat; 2001 Jul; 8(4):243-8. PubMed ID: 11454174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mutation analysis of ISDR and V3 domains of hepatitis C virus NS5A region before interferon therapy with or without ribavirin].
    Veillon P; Payan C; Gaudy C; Goudeau A; Lunel F
    Pathol Biol (Paris); 2004 Nov; 52(9):505-10. PubMed ID: 15531113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.
    Muñoz de Rueda P; Casado J; Patón R; Quintero D; Palacios A; Gila A; Quiles R; León J; Ruiz-Extremera A; Salmerón J
    J Virol; 2008 Jul; 82(13):6644-53. PubMed ID: 18448540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is investigation of hepatitis C virus NS5A gene heterogeneity a tool for predicting long-lasting response to interferon therapy in patients with HCV-1b chronic hepatitis?
    Squadrito G; Raffa G; Restuccia T; Pollicino T; Brancatelli S; Raimondo G
    J Viral Hepat; 2002 Sep; 9(5):360-9. PubMed ID: 12225331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study.
    Okanoue T; Itoh Y; Hashimoto H; Yasui K; Minami M; Takehara T; Tanaka E; Onji M; Toyota J; Chayama K; Yoshioka K; Izumi N; Akuta N; Kumada H
    J Gastroenterol; 2009; 44(9):952-63. PubMed ID: 19517057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy.
    Nousbaum J; Polyak SJ; Ray SC; Sullivan DG; Larson AM; Carithers RL; Gretch DR
    J Virol; 2000 Oct; 74(19):9028-38. PubMed ID: 10982347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity.
    Duverlie G; Khorsi H; Castelain S; Jaillon O; Izopet J; Lunel F; Eb F; Penin F; Wychowski C
    J Gen Virol; 1998 Jun; 79 ( Pt 6)():1373-81. PubMed ID: 9634077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic changes in the interferon sensitivity determining region of hepatitis C virus during the natural course of chronic hepatitis C.
    Maekawa S; Enomoto N; Kurosaki M; Nagayama K; Marumo F; Sato C
    J Med Virol; 2000 Jul; 61(3):303-10. PubMed ID: 10861637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.
    Vuillermoz I; Khattab E; Sablon E; Ottevaere I; Durantel D; Vieux C; Trepo C; Zoulim F
    J Med Virol; 2004 Sep; 74(1):41-53. PubMed ID: 15258967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between mutations in the interferon sensitivity-determining region of NS5A protein and viral load of hepatitis C virus subtypes 1b, 1c, and 2a.
    Lusida MI; Nagano-Fujii M; Nidom CA; Soetjipto ; Handajani R; Fujita T; Oka K; Hotta H
    J Clin Microbiol; 2001 Nov; 39(11):3858-64. PubMed ID: 11682498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy.
    Sarrazin C; Berg T; Lee JH; Teuber G; Dietrich CF; Roth WK; Zeuzem S
    J Hepatol; 1999 Jun; 30(6):1004-13. PubMed ID: 10406177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations in carboxy-terminal part of E2 including PKR/eIF2alpha phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: their correlation with response to interferon monotherapy and viral load.
    Ukai K; Ishigami M; Yoshioka K; Kawabe N; Katano Y; Hayashi K; Honda T; Yano M; Goto H
    World J Gastroenterol; 2006 Jun; 12(23):3722-8. PubMed ID: 16773689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.